Tempus AI, Inc. (TEM)
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
Tempus AI Hits $100—Are Shares Due for a Pullback?
Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on Monday, Oct. 13.
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Strategic Partnerships Power Tempus AI's Healthcare Expansion
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Tempus AI: TEM Stock To $130?
Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory and expanding market opportunity indicate room for continued upside, as outlined below.
Tempus AI's Strong Q2 Fuels Growth Story—More Upside Ahead?
Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI NASDAQ: TEM. In a world where healthcare IPOs are typically dominated by biotech companies that generate little to no revenue, Tempus stands out.
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Tempus AI Stock: Is It A Buy Following Guidance Raise?
Tempus AI delivered strong revenue growth and beat expectations on both revenue and profit, but remains unprofitable at this stage. Sequential improvements in both revenue and loss per share highlight progress, with annualized revenue growth tracking at an impressive rate. Despite the double beat, TEM stock price showed little movement, likely due to high investor expectations and prior consensus outperformance.
